Showing results (1-10 of 410) with videos related to
Sort By:
Pageof 41
Clinical Advances in Hematology & Oncology : H&O|December 16, 2010
Advances in targeted therapy for melanomaPhilip Friedlander, F Stephen HodiAsia-Pacific Journal of Clinical Oncology|May 21, 2010
Overcoming immunological tolerance to melanoma: Targeting CTLA-4F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Cytotoxic T-lymphocyte-associated antigen-4F Stephen HodiCancer Immunology Research|April 30, 2014
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysisLe Min, F Stephen HodiJournal of Cutaneous Pathology|May 21, 2010
The biologic importance of tumor-infiltrating lymphocytesF Stephen Hodi, Glenn DranoffThe Journal of Clinical Investigation|September 2, 2015
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockadeElizabeth Buchbinder, F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2016
Talimogene Laherparepvec for the Treatment of Advanced MelanomaPatrick A Ott, F Stephen HodiThe Oncologist|May 28, 2013
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaJason J Luke, F Stephen HodiClinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2011
Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanomaJason J Luke, F Stephen HodiPageof 41